- Poster presentation
- Open Access
Time course of myocardial oedema in acute coronary syndrome assessed at 3 T using a bright blood T2-prepared SSFP sequence
© Dall'Armellina et al; licensee BioMed Central Ltd. 2010
- Published: 21 January 2010
- Percutaneous Coronary Intervention
- Acute Coronary Syndrome
- Cardiac Magnetic Resonance
- Late Gadolinium Enhancement
- Acute Coronary Syndrome Patient
Cardiac magnetic resonance (CMR) is used in the evaluation of acute coronary syndrome (ACS) to assess both area at risk (AaR) and area of necrosis. However, the time course and evolution of myocardial oedema in patients with ACS is not known. We sought to assess the change in myocardial oedema following percutaneous coronary intervention (PCI) in patients with ST-elevation myocardial infarction (STEMI) and non-ST elevation ACS (NSTE-ACS).
Patients admitted with NSTE-ACS who underwent PCI within 24 hours, or with STEMI were imaged using CMR (Siemens Trio 3 T) at 24-48 hours (E1) and 5-7 days (E2) post PCI. STEMI patients were also imaged at 14-17 days (E3). The imaging protocol included short axis images covering the entire left ventricle (LV) acquired using T2-prepared SSFP sequence and late gadolinium enhancement (LGE). Percentage of myocardial oedema (oedema area/LV slice area: AaR) and myocardial scar were assessed offline.
We identified two groups of male patients (6 STEMI and 6 NSTE-ACS) matched for age (54 ± 8 yrs vs 59 ± 13 yrs) and AaR at E1 (24 ± 15% and 23 ± 14%).
In NSTEMI patients, AaR decreased to 15.6% (p = 0.10) between E1 and E2. In contrast, in STEMI AaR increased from 24 ± 15% at E1 to 31 ± 15% 5-7 days post PCI (E2). By 14-17 days (E3) there was a significant decrease in oedema (20 ± 13%) in this group.
For equivalent initial area at risk at E1, patients with STEMI have larger scar and more persistent oedema. Myocardial oedema post PCI decreases in NSTE-ACS within 7 days, but increases in STEMI. These dynamic changes highlight the importance of CMR in ACS patients and suggest the need to define the optimal time point to assess area at risk.
This article is published under license to BioMed Central Ltd.